FCT iStream Phase 2
Fujifilm Corporation · Decision date Sep 4, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K253836, FCT iStream Phase 2, on 2026-09-04. The submission was received 12/01/2025 and listed under device classification name System, X-Ray, Tomography, Computed, regulation number 892.1750, product code JAK, with radiology as the regulation medical specialty and review panel. The applicant is Fujifilm Corporation; the correspondent is FUJIFILM Healthcare Americas Corporation. The record describes a traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan.
SESE means FDA found the submission substantially equivalent to a legally marketed predicate device, which is a clearance rather than premarket approval. The record does not identify the predicate device, the specific components or changes distinguishing Phase 2 from earlier versions, or the contents of any summary; those details would need the underlying submission documents. No clinical, efficacy or labeling conclusions are drawn here.
The page lists a last-updated date of 10/26/2026, later than the decision date, and the source provides no statement text.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K253836
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Fujifilm Corporation
- Product code
- JAK
- Decision code
- SESE
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, X-Ray, Tomography, Computed.
- Applicant
- Fujifilm Corporation
- Product code
- JAK
- FDA device class
- 2
FDA decision timeline
K253836 received
Application receipt date recorded by FDA.
K253836 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JAK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AVIEW Aorta MetricsK260391 | Coreline Soft Co., Ltd. | 510(k) clearance | Oct 16, 2026 | FDA |
CAS-One IRK261225 | Cascination AG | 510(k) clearance | Sep 29, 2026 | FDA |
| Samsung HME America, Inc., dba NeuroLogica Corp. | 510(k) clearance | Sep 22, 2026 | FDA | |
SCENARIA View Phase 6.0K261229 | Fujifilm Corporation | 510(k) clearance | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Fujifilm Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Minato-Ku
Sources and methodology
- Original FDA record: K253836
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

